ClinicalTrials.gg
CompletedNCT05145621Updated Dec 21, 2021

Oral Bio-equivalence Study

A Phase 1 interventional study of Fingolimod 0.5 mg capsules- Test drug in Bioequivalence and Safety, sponsored by Alembic Pharmaceuticals Ltd.. Completed at 1 site in Canada. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-21.

Sponsored by Alembic Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Title of Study: An Open-Label, Balanced, Randomized, 2-Treatment, 2-Sequence, 2-Period, Single Dose, Crossover Oral Bioequivalence Study of Two Formulations of Fingolimod Capsules (3 x 0.5 mg) in Healthy Adult Human Subjects Under Fasting Conditions.

Objective: The objective of this study is to compare the oral bioavailability and characterize the pharmacokinetic profile of the test formulation relative to that of reference formulation in healthy, adult, human subjects under fasting conditions and to assess the bioequivalence.

02

Conditions studied

  • Bioequivalence
  • Safety
03

In context

Lead sponsor

Alembic Pharmaceuticals Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Volunteers meeting all of the following criteria will be considered for enrollment in the study:

  1. Availability for the entire study period 2. Motivated volunteer and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee 3. Male or female volunteer 4. A female volunteer must meet one of the following criteria:
  1. Physiological status, defined as the following:

    1. no menses for at least one year (absence of menses should not be due to lactational amenorrhea); and
    2. FSH levels ≥ 40 mIU/mL at screening; or
  2. Surgical postmenopausal status, defined as the following:

    1. bilateral oophorectomy; and
    2. absence of menses for at least 3 months; and
    3. FSH levels ≥ 40 mIU/mL at screening; or
  3. Hysterectomy with FSH levels ≥ 40 mIU/mL at screening If the postmenopausal volunteer has an FSH of \< 40 mIU/mL, but meets the above criteria in either (1), (2) or (3) and all the other inclusion criteria in section 5.2, the volunteer may be included in the study if the estradiol serum level measured at screening is equal to or below 150 pmol/L. In the case of hysterectomy, if FSH and estradiol do not meet the criteria, inclusion of the volunteer will be based on medical judgment. 5. Volunteer aged of at least 18 years but not older than 45 years 6. Volunteer with a greater than or equal to 18.50 kg/m2 and below 30.00 kg/m2 7. Volunteer with a minimum body weight of at least 60 kg 8. Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking and/or using tobacco/tobacco-containing products for at least 6 months before day 1 of this study 9. Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance 10. Have no diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, general biochemistry, and urinalysis) 11. Willingness to adhere to the protocol requirements as evidenced by the form (ICF) duly read, signed and dated by the volunteer 12. Volunteer agrees not to participate in another clinical study for up to 10 weeks following the last drug administration The ICF must be signed by all volunteers prior to their participation in the study.

Exclusion criteria

Exclusion Criteria:

Volunteers presenting any of the following will not be included in the study:

  1. Difficulty donating blood
  2. Difficulty swallowing solids like tablets or capsules
  3. Seated pulse rate less than 60 bpm or more than 100 bpm at screening
  4. History of significant to fingolimod or any related products (including of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
  5. Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
  6. History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability
  7. History or presence of significant cardiovascular, respiratory, pulmonary, hepatic, renal, gastrointestinal, ophthalmological, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
  8. Suicidal tendency, history of or disposition to seizures, state of confusion, psychiatric diseases or disorder
  9. Presence of out-of-range cardiac interval (PR \< 110 msec, PR > 200 msec, QRS \< 60 msec, QRS >110 msec and > 440 msec)
  10. History of using within 56 days before day 1 of this study
  11. Immunization with a vaccine within 28 days before day 1 of this study
  12. Use of in the 28 days before day 1 of this study
  13. Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  14. Any clinically significant illness in the previous 28 days before day 1 of this study
  15. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, , phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study
  16. Any history of latent or active tuberculosis and/or prophylaxis for tuberculosis according to the TB Medical History screening questionnaire (see Appendix 1)
  17. Positive tuberculin blood or skin test
  18. Herpes IgG (Type 1) and/or IgG (Type 2) antibody levels that may predispose to undesired effects, as per medical judgment
  19. Positive urine screening of drugs of abuse
  20. Positive alcohol breath test
  21. Positive results to HIV Ag/Ab Combo, surface Antigen (HBsAG (B)(hepatitis B)) or anti- Virus (HCV (C)) tests
  22. Females who are pregnant according to a positive pregnancy test
  23. Volunteers who took an Product (in another clinical trial) with a long half-life (≥120 hours) in the previous 3 months before day 1 of this study
  24. Volunteers who took an Investigational Product (in another clinical trial) with a half-life less than 120 hours in the previous 28 days before day 1 of this study or who have already participated in this clinical study
  25. Volunteers who donated 50 mL or more of blood in the previous 28 days before day 1 of this study
  26. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    Test

    Fingolimod 0.5 mg capsules - (administered as 3 x Fingolimod 0.5 mg capsules)

    Drug: Fingolimod 0.5 mg capsules- Test drug

  • Active comparator
    Reference

    Fingolimod 0.5 mg capsules -(administered as 3 x Fingolimod 0.5 mg capsules)

    Drug: Fingolimod 0.5 mg capsules- Test drug

Interventions

  • An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.

    Also known as: Fingolimod 0.5 mg capsules- Reference drug

06

What researchers measure

Primary outcomes

  1. Cmax- Peak Plasma concentration

    Peak Plasma concentration of Test product should be comparable with Reference product

    Time frame: upto 72 hours

  2. AUC0-72

    Area Under the Concentration of Test product should be comparable with Reference product

    Time frame: upto 72 hours

07

Study locations

1 site
  • Algorithme Pharma Inc.
    Mount-Royal, Quebec H3P 3H5, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Jan 2016, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2015
First posted
Dec 6, 2021
StartActual
Oct 29, 2015
Primary completionActual
Jan 15, 2016
CompletionActual
Jan 15, 2016
Last update
Dec 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05145621
Lead sponsor
Alembic Pharmaceuticals Ltd.
Responsible party
Sponsor
First posted
Dec 6, 2021
Start date
Oct 29, 2015
Primary completion
Jan 15, 2016
Completion
Jan 15, 2016
Last update
Dec 21, 2021

Study contacts

Eric Sicard, M.D.
principal investigator · Algorithme Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion